NCT00449046已完成3 期
Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 3
- 主要终点
- Most Frequent Adverse Events - On Therapy
研究概览
简要总结
This study evaluates the long-term (24-week) safety and efficacy of GW815SF Salmeterol/fluticasone propionate(HFA MDI) 50/100mcg(administered as 2 inhalations of 25/50mcg) bid in pediatric patients with bronchial asthma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 14 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria for Entry in Run-in Period
- •A pediatric patient already diagnosed as having bronchial asthma who meets all of the following criteria is eligible for the study:
- •Male or female patients aged ≥5 and ≤14 years. Enrolment of a female patient of childbearing potential is allowed only if she is tested negative in the pregnancy testing at the start of treatment period and if she agrees to undergo pregnancy testing at the protocol-specified timings and to take contraceptive measures without fail during the study period.
- •Written informed consent must be obtained from the legally acceptable representative of the subject. Consent of the subject him/herself should also be obtained, wherever possible, after giving an explanation in an as easy to understand as possible manner.
- •An outpatient who has been treated with ICS (FP 100-200μg/day or equivalent) for at least 4 weeks prior to Visit
- •Is suitable, in the investigator's/subinvestigator's judgment, for treatment with GW815SF HFA MDI 25/50μg (administered as 2 inhalations of 25/50μg) bid.
- •Able to use a peak flow meter in a correct manner in the investigator's/subinvestigator's judgment.
- •Able to use MDI in a correct manner (with the assistance of his/her caregiver as necessary) in the investigator's/subinvestigator's judgment.
- •Inclusion Criteria for Entry in Treatment Period A subject will be considered eligible for inclusion in the treatment period only if he/she has completed the run-in period and meets the following criterion.
- •1. Has been able, in the investigator's/subinvestigator's judgment, to make entries in the asthma diary and measure PEF, as directed, during the run-in period.
排除标准
- •Exclusion Criteria for Entry in Run-in Period
- •A patient who applies any of the following criteria is not eligible for the study:
- •Admitted to the hospital due to asthma exacerbation within 8 weeks prior to Visit
- •Used systemic steroid within 4 weeks prior to Visit
- •Received antibacterials or antivirals for treatment of upper or lower respiratory tract infection within 2 weeks prior to Visit
- •Has a safety problem in participation in the study because of a serious, uncontrolled systemic disease including nervous system disorder.
- •Has or is suspected to have deep-seated mycosis or infection to which no effective antibacterial agent is available.
- •Has or is suspected to have hypersensitivity to the investigational product, rescue medication or any ingredients of them.
- •Is pregnant or lactating, may be pregnant, or plans for pregnancy during the study period.
- •Has received the last dose in another clinical study within 2 months prior to this study.
- •Is not eligible for the study in the investigator's/subinvestigator's judgment.
- •Exclusion Criteria for Entry in Treatment Period
- •A subject who applies to any of the following criteria is not eligible for the study:
- •Admitted to the hospital due to asthma exacerbation during the run-in period.
- •Had upper or lower respiratory tract infection during the 2 weeks just before Visit
- •Used prohibited drugs during the 2 weeks just before Visit
- •Is not eligible for the study in the investigator's/subinvestigator's judgment.
结局指标
主要结局
Most Frequent Adverse Events - On Therapy
时间窗: Baseline to Week 24
Adverse events, Clinical laboratory tests, Adrenocortical function test, Physical examinations, 12-lead electrocardiogram (ECG), Oropharyngeal examination were included.
Serious Adverse Events (SAEs) - On Therapy
时间窗: Baseline to Week 24
Number of participants considered by the investigator to be related to study medication. Adverse events, Clinical laboratory tests, Adrenocortical function test, Physical examinations, 12-lead ECG, Oropharyngeal examination were included. Frequency threshold of reported SAE's is 0%(100% reported)
次要结局
- Change From Baseline in Morning Peak Expiratory Flow (PEF) During Weeks 1-24(Baseline and during Weeks 1-24)
- Change From Baseline in Percent Predicted Morning Peak Expiratory Flow (PEF) During Weeks 1-24(Baseline and during Weeks 1-24)
- Change From Baseline in Evening Peak Expiratory Flow (PEF) During Weeks 1-24(Baseline and during Weeks 1-24)
- Change From Baseline in Circadian Variation in Peak Expiratory Flow (PEF) During Weeks 1-24(Baseline and during Weeks 1-24)
- Number of Participants With Symptom-Free Nights and Days(Baseline and Week 24)
- Number of Participants With Rescue Medication-Free Nights and Days(Baseline and Week 24)
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
1 期
Assessment of Salmeterol/fluticasone propionate in children with bronchial asthma.AsthmaEUCTR2015-004881-27-Outside-EU/EEAGlaxoSmithKline Research & Development Ltd40
终止
4 期
Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPDCOPDNCT03363503Neutec Ar-Ge San ve Tic A.Ş64
进行中（未招募）
不适用
Efficacy and safety of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ Accuhaler™ in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, double-blind, double-dummy, parallel group studymoderate-to-severe persistent asthmaMedDRA version: 9.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2007-005620-32-LTHEXAL AG472
进行中（未招募）
1 期
Efficacy and safety of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ Accuhaler™ in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, double-blind, double-dummy, parallel group studymoderate-to-severe persistent asthmaMedDRA version: 9.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2007-005620-32-PLHEXAL AG472
进行中（未招募）
不适用
Efficacy and safety of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ Accuhaler™ in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, double-blind, double-dummy, parallel group studymoderate-to-severe persistent asthmaMedDRA version: 9.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2007-005620-32-HUHEXAL AG472